Abcam Plc’s (ABC) Sell Rating Reiterated at Panmure Gordon

Abcam Plc (LON:ABC)‘s stock had its “sell” rating reissued by Panmure Gordon in a research report issued to clients and investors on Monday. They currently have a GBX 680 ($8.31) price objective on the stock. Panmure Gordon’s target price indicates a potential downside of 19.23% from the company’s previous close.

ABC has been the topic of a number of other research reports. JPMorgan Chase & Co. reissued a “neutral” rating and issued a GBX 678 ($8.29) price target on shares of Abcam Plc in a research note on Wednesday, January 4th. Peel Hunt reissued a “hold” rating and issued a GBX 750 ($9.17) price target on shares of Abcam Plc in a research note on Friday, February 24th. Finally, Numis Securities Ltd reissued an “add” rating and issued a GBX 870 ($10.64) price target on shares of Abcam Plc in a research note on Tuesday, January 10th. One investment analyst has rated the stock with a sell rating and five have given a hold rating to the company’s stock. Abcam Plc presently has a consensus rating of “Hold” and an average target price of GBX 726 ($8.88).

Analyst Recommendations for Abcam Plc (LON:ABC)

Shares of Abcam Plc (LON:ABC) opened at 841.00 on Monday. Abcam Plc has a 12 month low of GBX 577.00 and a 12 month high of GBX 948.00. The firm has a 50-day moving average of GBX 863.26 and a 200 day moving average of GBX 828.85. The firm’s market cap is GBX 1.70 billion.

The firm also recently disclosed a dividend, which will be paid on Thursday, April 13th. Shareholders of record on Thursday, March 16th will be given a dividend of GBX 2.83 ($0.03) per share. The ex-dividend date of this dividend is Thursday, March 16th. This represents a yield of 0.31%.

Your IP Address:

Abcam Plc Company Profile

Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company’s purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways.

This story was originally published by sleekmoney ( and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at

Receive News & Ratings for Abcam Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam Plc and related companies with's FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *